Storia in 3 fonti

Definium Therapeutics, Inc. Announces Proposed Public Offering

Raccontata da

morningstar.com

benzinga.com

zerohedge.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics launches $500M public offering to fund DT120 ODT, a psychedelic-assisted therapeutic for psychiatric and neurological disorders. The capital raise signals biotech-backed psychedelic therapy as an emerging market category for healthcare-focused investors.

originale

benzinga.com1 mese fa

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.

Leggi questa versione →

Timeline cronologica

domenica 21 giugno 2026·morningstar.com
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
lunedì 22 giugno 2026·benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…

Definium Therapeutics, Inc. Announces Proposed Public Offering

Confronto fonti

Definium Therapeutics, Inc. Announces Proposed Public Offering

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Timeline cronologica

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

Definium Therapeutics, Inc. Announces Proposed Public Offering

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering